A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.

Chu MatsudaMichitaka HondaChihiro TanakaKen KondoTakao TakahashiChihiro KosugiYukihiko TokunagaHiroyoshi TakemotoHo Min KimJunichi SakamotoKoji ObaHideyuki Mishima

Published in: Cancer chemotherapy and pharmacology (2018)

The alternate-day S-1 administration does not have significant effectiveness to reduce diarrhea in patients who received second-line treatment for metastatic colorectal cancer.

Keyphrases

metastatic colorectal cancer
phase ii study
open label
randomized controlled trial
systematic review
locally advanced
squamous cell carcinoma
stem cells
clinical trial
bone marrow
combination therapy
irritable bowel syndrome
placebo controlled